Cyclization enhances function of linear anti-arthritic peptides

Cyclization enhances function of linear anti-arthritic peptides

© 2013. Published by Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 150(2014), 1 vom: 11. Jan., Seite 121-33
Auteur principal: Ali, Marina (Auteur)
Autres auteurs: Amon, Michael, Bender, Vera, Bolte, Andrea, Separovic, Frances, Benson, Heather, Manolios, Nicholas
Format: Article en ligne
Langue:English
Publié: 2014
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine 1,2-dimyristoyl-sn-glycero-3-phosphatidylglycerol 3-(N-morpholino) propane sulfonic acid AA ACD Arthritis Asthma At-Column Dilution plus... BALF C1 C1-L CP DIEA DMF DMPC DMPG DMSO FDPP HEPES IL Inflammation MOPS MTB Mycobacterium tuberculosis N,N-diisopropylethylamine N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid NMR PBL PG PMA Peptides Phorbol 12-myristate 13-acetate (PMA) SEA SPR SUV T cell antigen receptor T cells TCR TFA amino acid bronchoalveolar lavage fluid core peptide cyclic peptide 1 dimethylformamide dimethylsulfoxide interleukin linear sequence of C1 nuclear magnetic resonance pentafluorophenyl diphenylphosphinate peripheral blood lymphocyte propylene glycol small unilamellar vesicles staphylococcal enterotoxin A surface plasmon resonance trifluoroacetic acid. Anti-Inflammatory Agents Cytokines Peptides, Cyclic
LEADER 01000caa a22002652 4500
001 NLM232444226
003 DE-627
005 20250216052806.0
007 cr uuu---uuuuu
008 231224s2014 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2013.10.005  |2 doi 
028 5 2 |a pubmed25n0774.xml 
035 |a (DE-627)NLM232444226 
035 |a (NLM)24207019 
035 |a (PII)S1521-6616(13)00263-5 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Ali, Marina  |e verfasserin  |4 aut 
245 1 0 |a Cyclization enhances function of linear anti-arthritic peptides 
264 1 |c 2014 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 11.03.2014 
500 |a Date Revised 20.11.2014 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2013. Published by Elsevier Inc. All rights reserved. 
520 |a This study describes the biophysical and immunomodulatory features of a cyclic peptide termed C1 which consists of alternating d-, l-amino acids and is capable of inhibiting IL-2 production in vitro and reducing the induction and extent of T-cell mediated inflammation in animal models. Solid-state nuclear magnetic resonance demonstrates that the peptide orders the lipid bilayer, suggesting a transmembrane orientation, and this is supported by surface plasmon resonance indicating strong binding affinity of C1 to model membranes. In vitro cell viability and proliferation assays show that C1 does not disrupt the integrity of cell surface membranes. Permeation studies of C1 and analogs across human epidermis cells show that the stability and skin permeability are enhanced by cyclization. Treatment with C1 in an asthma and in an arthritis animal model resulted in a suppressed immune response. Cyclization may be a useful means of enhancing biological linear peptide activity and improving delivery 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine 
650 4 |a 1,2-dimyristoyl-sn-glycero-3-phosphatidylglycerol 
650 4 |a 3-(N-morpholino) propane sulfonic acid 
650 4 |a AA 
650 4 |a ACD 
650 4 |a Arthritis 
650 4 |a Asthma 
650 4 |a At-Column Dilution 
650 4 |a BALF 
650 4 |a C1 
650 4 |a C1-L 
650 4 |a CP 
650 4 |a DIEA 
650 4 |a DMF 
650 4 |a DMPC 
650 4 |a DMPG 
650 4 |a DMSO 
650 4 |a FDPP 
650 4 |a HEPES 
650 4 |a IL 
650 4 |a Inflammation 
650 4 |a MOPS 
650 4 |a MTB 
650 4 |a Mycobacterium tuberculosis 
650 4 |a N,N-diisopropylethylamine 
650 4 |a N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid 
650 4 |a NMR 
650 4 |a PBL 
650 4 |a PG 
650 4 |a PMA 
650 4 |a Peptides 
650 4 |a Phorbol 12-myristate 13-acetate (PMA) 
650 4 |a SEA 
650 4 |a SPR 
650 4 |a SUV 
650 4 |a T cell antigen receptor 
650 4 |a T cells 
650 4 |a TCR 
650 4 |a TFA 
650 4 |a amino acid 
650 4 |a bronchoalveolar lavage fluid 
650 4 |a core peptide 
650 4 |a cyclic peptide 1 
650 4 |a dimethylformamide 
650 4 |a dimethylsulfoxide 
650 4 |a interleukin 
650 4 |a linear sequence of C1 
650 4 |a nuclear magnetic resonance 
650 4 |a pentafluorophenyl diphenylphosphinate 
650 4 |a peripheral blood lymphocyte 
650 4 |a propylene glycol 
650 4 |a small unilamellar vesicles 
650 4 |a staphylococcal enterotoxin A 
650 4 |a surface plasmon resonance 
650 4 |a trifluoroacetic acid. 
650 7 |a Anti-Inflammatory Agents  |2 NLM 
650 7 |a Cytokines  |2 NLM 
650 7 |a Peptides, Cyclic  |2 NLM 
700 1 |a Amon, Michael  |e verfasserin  |4 aut 
700 1 |a Bender, Vera  |e verfasserin  |4 aut 
700 1 |a Bolte, Andrea  |e verfasserin  |4 aut 
700 1 |a Separovic, Frances  |e verfasserin  |4 aut 
700 1 |a Benson, Heather  |e verfasserin  |4 aut 
700 1 |a Manolios, Nicholas  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 150(2014), 1 vom: 11. Jan., Seite 121-33  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:150  |g year:2014  |g number:1  |g day:11  |g month:01  |g pages:121-33 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2013.10.005  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 150  |j 2014  |e 1  |b 11  |c 01  |h 121-33